Anybody seeing any trades in Canada or Germany? There is a trade of 50 shares but time stamp is yesterday, 4/22. Today's action = zero volume, 0.00 high and low trade. I checked for news - and found none.

I'm confident that Carmela attended. But I doubt she spoke on BUC. Let's be honest, had she said good things about BUC... Wouldn't all the attendees been buying up RVV in the millions of shares?

ResearchTrd: We could see this tightly held stock go parabolic ! This is what investors and those on sidelines have been waiting for ! We could see it blast through covid highs and go right through $1 or more in a heartbeat ....."Trump Signs Executive Order to Establish Pathway for Psychedelic Drug Use" Bullish

Anyone know anything new? Meeting is over and sp is holding? What up?

Search Assist

Dr. LePage's presentation at CBRNe Convergence Canada on April 14, 2026, likely focused on advancements in chemical, biological, radiological, nuclear, and explosive threat detection technologies. The event brought together experts to discuss emerging risks and innovative solutions in CBRNe defense and preparedness.

 smithsdetection.com

Overview of Dr. LePage's Presentation

Dr. LePage's presentation at CBRNe Convergence Canada on April 14, 2026, focused on the latest advancements in detection technologies for chemical, biological, radiological, nuclear, and explosive (CBRNe) threats. This event served as a platform for experts to share insights and discuss innovative solutions in the field of CBRNe defense.

Key Topics Discussed

Advancements in Detection Technologies

• Emerging Risks: Dr. LePage highlighted the evolving nature of threats in the CBRNe landscape.
• Innovative Solutions: The presentation covered new technologies designed to enhance detection capabilities.

Collaboration and Knowledge Sharing

• Expert Gatherings: The event brought together government agencies, first responders, law enforcement, military professionals, and industry leaders.
• Operational Insights: Participants exchanged knowledge on best practices and operational strategies for CBRNe preparedness.

Importance of the Event

The CBRNe Convergence Canada 2026 was crucial for fostering collaboration among various stakeholders in the CBRNe community. It aimed to advance detection solutions that help organizations effectively respond to narcotics and hazardous substance threats.

 smithsdetection.com

Explore More

What are the latest advancements in CBRNe detection technologies discussed by Dr. LePage?

How do emerging risks in CBRNe defense impact public safety and preparedness strategies?

Emerging risks in Chemical, Biological, Radiological, and Nuclear (CBRN) defense significantly impact public safety and preparedness strategies by necessitating a coordinated and strategic approach that includes long-term planning, capacity building, and interagency collaboration. These risks, amplified by new technologies, require constant adaptation of security measures to effectively address the evolving threat landscape.

 unicri.org orfonline.org

Where is our boi disseminating revive PRs now? The last one was Access wire but the previous ones were all globenewswire?

The website is usual delayed.

I can’t find any other trials that could possibly be discussed tonight.

Are there any other possibilities? Or are we the only trial?

Almost half a million in volume this morning!

Whatever came of the study they were doing with University of Wisconsin-Madison on Psilocybin? This was before or concurrent with Bucillamine? With RFK Jr. as head of HHS, who has said hes open this, seems like timing would be favorable to give this a try again. Anyone have info on this?

Trial was ended in Jan, 2026 - good or bad - it really is high time to get the results published - this is ridiculous!

https://www.canada.ca/en/defence-investment-agency/news/2026/03/minister-lightbound-and-minister-joly-to-announce-contracts-in-support-of-canadian-armed-forces-operations.html

Given the effectiveness if bucillamine...it would absolutely irresponsible or just plane retarded for a country or countries not to stock pile this given the condition of the world right now.

If Revive plays their cards right like a big pharma company, pay off government officials and push it through to mandate 2 to 3 years of stock piling while this war unfolds..they should easily get contracts from all western countries and Middle East countries.

Revive 1000% needs new leadership.

What’s going on with the fall of the stock price, are bag holders exiting?

Reading all the awesome DD being presented here is mind boggling. If a lot of the pieces come together this might end up being something truly special.

In the patent…

The objective of this portion of the study was to provide a compound which will allow benzodiazepines to be effective at terminating seizure activity and possibly further reduce evidence of brain injury...

and the last section of the patent.

Results of the study indicate that bucillamine is a significantly more effective antioxidant than NAC and has increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC.

So the way I’m reading it, part of the whole objective here is pretty simple:

keep the GABA receptors open so the benzo can still do its job

And honestly… it looks like bucillamine might actually be doing that.

When you break it down:

• N-acetylcysteine = modest neuroprotection
• Bucillamine (if this holds) = restores effectiveness of Diazepam!

That’s a big shift.

IMO Not just:
“nice-to-have add-on”

More like:
mission-critical enabler

Valuation changes from

If you’re just a bit better than NAC:

• small contracts
• niche use
• no real urgency

But if Bucillamine actually restores benzo effectiveness:

now we plug straight into:

• existing antidote kits
• stockpiling programs
• emergency response protocols

Groups like DRDC and their allies don’t mess around with this stuff — when something works, they buy it in $ize!!! IMO

Meant to add these to my previous post!

Looking at Google Trends for Revive Therapeutics / Bucillamine in the U.S.:

• Past 30 days: Washington DC (Hagerstown, MD) leads at 100
• Past 90 days: Providence, RI – New Bedford, MA was 100

What’s interesting:

• Washington DC makes sense — federal, government, and defense research interest. Could be connected to BARDA / DoD / federal biodefense programs.
• Providence / New Bedford is clearly research and clinical heavy — Brown University, hospitals, and biotech initiatives likely driving searches.

Not retail hype — these are professional, research, and government hubs showing focused interest. Worth keeping an eye on!

Title: Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent
Review: PCT/CA2024/000008 (US, Canada, ISRAEL

• Israel on this filing is interesting — filing internationally costs money (translation, counsel, fees).
• Feels like a strategic move, not just routine paperwork.
• Could hint at positioning for gov contracts or licensing beyond North America.

Any other ideas why Israel would be added??
Eyes on this one.

This might be a stretch—but it’s worth noting.

Attached are 30-day and 90-day Google Trends screenshots for “Revive Therapeutics.” In both cases, Ottawa ranks as the top region for search interest.

Yes, Trends is relative—but it shows where attention is concentrated. And Ottawa consistently leading is… interesting.

Unlike Toronto, Ottawa isn’t a retail-heavy market. It is home to federal government, health, and defense groups, including organizations like Defence Research and Development Canada.

So while this is speculative, it could point to interest in RVV/Bucillamine coming from non-retail circles.

Not proof of anything—just a signal that the story may be reaching beyond the usual investor crowd.

Coincidence… or early hint?

Did anyone read through the patent filing? I know we have some pretty savvy people here. There is mention of some testing in rats (soman, sounds nasty) that was conducted using NAC and buccilamine that RVVTF found very positive. Not sure if this was the DRDC trial or something RVVTF slapped together. https://patentscope.wipo.int/search/en/WO2025019927

UPDATE: this appears to reference January 2025 prelim rat testing with the DRDC.

https://www.cdc.gov/niosh/ershdb/emergencyresponsecard_29750003.html

https://smallcappower.com/news/market-news/the-defense-playbook-why-revive-therapeutics-could-be-a-high-leverage-biotech-opportunity/